289 related articles for article (PubMed ID: 34374773)
41. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
42. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
43. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
Dylag AM; Shah SI
Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
[TBL] [Abstract][Full Text] [Related]
44. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
45. Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children.
Lee SM; Kim SJ; Chen J; Song R; Kim JH; Devadiga R; Kim YK
Hum Vaccin Immunother; 2019; 15(5):1145-1153. PubMed ID: 30668217
[TBL] [Abstract][Full Text] [Related]
46. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
[TBL] [Abstract][Full Text] [Related]
47. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
Wanlapakorn N; Maertens K; Thongmee T; Srimuan D; Thatsanathorn T; Van Damme P; Leuridan E; Poovorawan Y
Vaccine; 2020 Oct; 38(44):6914-6921. PubMed ID: 32888740
[TBL] [Abstract][Full Text] [Related]
48. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
Front Immunol; 2018; 9():51. PubMed ID: 29416544
[TBL] [Abstract][Full Text] [Related]
49. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
Scott LJ
BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
[TBL] [Abstract][Full Text] [Related]
50. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Liang JL; Tiwari T; Moro P; Messonnier NE; Reingold A; Sawyer M; Clark TA
MMWR Recomm Rep; 2018 Apr; 67(2):1-44. PubMed ID: 29702631
[TBL] [Abstract][Full Text] [Related]
51. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
[TBL] [Abstract][Full Text] [Related]
52. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
53. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
54. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.
Sun Y; Christensen J; Hviid A; Li J; Vedsted P; Olsen J; Vestergaard M
JAMA; 2012 Feb; 307(8):823-31. PubMed ID: 22357833
[TBL] [Abstract][Full Text] [Related]
55. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
[TBL] [Abstract][Full Text] [Related]
56. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
57. Timeliness of childhood vaccination in the Federated States of Micronesia.
Tippins A; Leidner AJ; Meghani M; Griffin A; Helgenberger L; Nyaku M; Underwood JM
Vaccine; 2017 Nov; 35(47):6404-6411. PubMed ID: 29029941
[TBL] [Abstract][Full Text] [Related]
58. Absence of a significant interaction between a Haemophilus influenzae conjugate vaccine combined with a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine in the same syringe and inactivated polio vaccine.
Daum RS; Zenko CE; Given GZ; Ballanco GA; Parikh H; Vidor E; Liu X
Pediatr Infect Dis J; 2000 Aug; 19(8):710-7. PubMed ID: 10959738
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
Tanaka M; Okubo R; Hoshi SL; Ishikawa N; Kondo M
Vaccine; 2022 Feb; 40(7):1010-1018. PubMed ID: 35039195
[TBL] [Abstract][Full Text] [Related]
60. [Time for booster doses against whooping cough for 10-year-old children].
Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]